MX359413B - Metodos de tratamiento de carcinoma hepatocelular. - Google Patents
Metodos de tratamiento de carcinoma hepatocelular.Info
- Publication number
- MX359413B MX359413B MX2016015444A MX2016015444A MX359413B MX 359413 B MX359413 B MX 359413B MX 2016015444 A MX2016015444 A MX 2016015444A MX 2016015444 A MX2016015444 A MX 2016015444A MX 359413 B MX359413 B MX 359413B
- Authority
- MX
- Mexico
- Prior art keywords
- hepatocellular carcinoma
- treatment
- methods
- taxane
- nanoparticles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31815310P | 2010-03-26 | 2010-03-26 | |
| PCT/US2011/030037 WO2011119988A1 (en) | 2010-03-26 | 2011-03-25 | Methods of treatment of hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX359413B true MX359413B (es) | 2018-09-27 |
Family
ID=44673662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016015444A MX359413B (es) | 2010-03-26 | 2011-03-25 | Metodos de tratamiento de carcinoma hepatocelular. |
| MX2012010936A MX346861B (es) | 2010-03-26 | 2011-03-25 | Metodos de tratamiento de carcinoma hepato celular. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012010936A MX346861B (es) | 2010-03-26 | 2011-03-25 | Metodos de tratamiento de carcinoma hepato celular. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9370494B2 (enExample) |
| EP (2) | EP2552438B1 (enExample) |
| JP (2) | JP5847156B2 (enExample) |
| KR (1) | KR101786142B1 (enExample) |
| CN (2) | CN103052385B (enExample) |
| AU (1) | AU2011230512B2 (enExample) |
| BR (1) | BR112012024349A2 (enExample) |
| CA (2) | CA3051495A1 (enExample) |
| DK (1) | DK2552438T3 (enExample) |
| ES (2) | ES2675212T3 (enExample) |
| HR (1) | HRP20160609T1 (enExample) |
| HU (1) | HUE027749T2 (enExample) |
| IL (2) | IL221886A (enExample) |
| LT (1) | LT2552438T (enExample) |
| MX (2) | MX359413B (enExample) |
| NZ (1) | NZ602382A (enExample) |
| PL (1) | PL2552438T3 (enExample) |
| PT (1) | PT2552438T (enExample) |
| TW (1) | TWI495467B (enExample) |
| WO (1) | WO2011119988A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| SI2301531T1 (sl) | 2005-02-18 | 2018-11-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| PL3311805T3 (pl) * | 2005-08-31 | 2020-07-27 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| LT2117520T (lt) * | 2006-12-14 | 2018-12-10 | Abraxis Bioscience, Llc | Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną |
| MX380318B (es) * | 2007-03-07 | 2025-03-12 | Abraxis Bioscience Llc | Nanoparticula que comprende rapamicina y albumina como agente anticancer. |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| KR20120044279A (ko) | 2009-04-15 | 2012-05-07 | 아브락시스 바이오사이언스, 엘엘씨 | 무-프리온 나노입자 조성물 및 방법 |
| BR112012024349A2 (pt) | 2010-03-26 | 2016-05-24 | Abraxis Bioscience Llc | métodos de tratamento de carcinoma hepatocelular |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| CN105147613A (zh) | 2010-03-29 | 2015-12-16 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| WO2012149451A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| ES2804323T3 (es) | 2013-03-12 | 2021-02-05 | Abraxis Bioscience Llc | Procedimientos de tratamiento de cáncer de pulmón |
| CN105246468A (zh) | 2013-03-14 | 2016-01-13 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
| KR102245421B1 (ko) | 2013-05-30 | 2021-04-29 | 큐라디즘 | 약학적 조성물, 이의 제조방법 및 이의 용도 |
| WO2015120273A1 (en) * | 2014-02-07 | 2015-08-13 | The General Hospital Corporation | Differential diagnosis of hepatic neoplasms |
| DK3229776T3 (da) | 2014-11-25 | 2023-07-31 | Curadigm Sas | Farmaceutisk sammensætning, der kombinerer mindst to særskilte nanopartikler og en farmaceutisk forbindelse, fremstilling og anvendelser deraf |
| TW201628644A (zh) * | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備及其用途 |
| MX388073B (es) | 2014-11-25 | 2025-03-19 | Nanobiotix | Composición farmacéutica, preparación y usos de la misma. |
| HUE056175T2 (hu) | 2014-11-25 | 2022-01-28 | Curadigm Sas | Gyógyászati készítmények, elõállításuk és alkalmazásaik |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| MA43100A (fr) | 2015-05-28 | 2018-09-05 | Nanobiotix | Nanoparticules à utiliser en tant que vaccin thérapeutique |
| AU2016285720C1 (en) | 2015-06-29 | 2022-02-03 | Abraxis Bioscience, Llc | Methods of treating epithelioid cell tumors |
| BR112019006329A2 (pt) * | 2016-10-07 | 2019-06-25 | Abraxis Bioscience Llc | métodos de tratamento de câncer do trato biliar |
| CN115487312B (zh) | 2016-10-27 | 2025-02-07 | 珠海贝海生物技术有限公司 | 多西他赛和人血清白蛋白的中性pH组合物 |
| US10896749B2 (en) * | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| CN107828887A (zh) * | 2017-10-12 | 2018-03-23 | 上海市东方医院 | Stmn1基因的用途 |
| SG11202009145PA (en) | 2018-03-20 | 2020-10-29 | Abraxis Bioscience Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| WO2021086946A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| WO2023072755A1 (en) * | 2021-10-26 | 2023-05-04 | Lipogems International S.P.A. | Microfragmented fat tissue as drug delivery system in liver cancer therapy |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| NZ502500A (en) | 1997-06-27 | 2002-03-28 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1171117A4 (en) | 1999-04-22 | 2002-08-07 | American Bioscience Inc | LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS |
| AU784416B2 (en) | 1999-05-21 | 2006-03-30 | Abraxis Bioscience, Llc | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB9920548D0 (en) | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| KR20110079741A (ko) | 2002-12-09 | 2011-07-07 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| SI2301531T1 (sl) * | 2005-02-18 | 2018-11-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CA2620389C (en) | 2005-08-31 | 2014-06-17 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| PL3311805T3 (pl) * | 2005-08-31 | 2020-07-27 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| CA2662140A1 (en) | 2006-08-31 | 2008-03-06 | Abraxis Bioscience, Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| WO2008036741A2 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| LT2117520T (lt) | 2006-12-14 | 2018-12-10 | Abraxis Bioscience, Llc | Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną |
| MX380318B (es) | 2007-03-07 | 2025-03-12 | Abraxis Bioscience Llc | Nanoparticula que comprende rapamicina y albumina como agente anticancer. |
| US20080255035A1 (en) * | 2007-04-13 | 2008-10-16 | Abraxis Bioscience, Inc. | Sparc and methods of use thereof |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| KR20100133475A (ko) | 2008-04-10 | 2010-12-21 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 그의 용도 |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| KR101739598B1 (ko) | 2009-03-13 | 2017-06-08 | 아브락시스 바이오사이언스, 엘엘씨 | 티오콜키신 유도체와의 조합 요법 |
| AU2010233097B2 (en) | 2009-04-10 | 2016-04-07 | Abraxis Bioscience, Llc | Nanoparticle formulations and uses thereof |
| KR20120044279A (ko) | 2009-04-15 | 2012-05-07 | 아브락시스 바이오사이언스, 엘엘씨 | 무-프리온 나노입자 조성물 및 방법 |
| SG10201609290PA (en) | 2009-08-25 | 2016-12-29 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| BR112012024349A2 (pt) | 2010-03-26 | 2016-05-24 | Abraxis Bioscience Llc | métodos de tratamento de carcinoma hepatocelular |
| CN105147613A (zh) | 2010-03-29 | 2015-12-16 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| EP2575803B1 (en) | 2010-06-02 | 2017-07-26 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| US20140155344A1 (en) | 2010-06-07 | 2014-06-05 | Neil P. Desai | Combination therapy methods for treating proliferative diseases |
| WO2012149451A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
-
2011
- 2011-03-25 BR BR112012024349A patent/BR112012024349A2/pt not_active Application Discontinuation
- 2011-03-25 DK DK11760333.2T patent/DK2552438T3/en active
- 2011-03-25 CA CA3051495A patent/CA3051495A1/en not_active Abandoned
- 2011-03-25 LT LTEP11760333.2T patent/LT2552438T/lt unknown
- 2011-03-25 KR KR1020127027815A patent/KR101786142B1/ko active Active
- 2011-03-25 MX MX2016015444A patent/MX359413B/es unknown
- 2011-03-25 US US13/583,603 patent/US9370494B2/en active Active
- 2011-03-25 CA CA2793536A patent/CA2793536C/en active Active
- 2011-03-25 EP EP11760333.2A patent/EP2552438B1/en active Active
- 2011-03-25 ES ES14200645.1T patent/ES2675212T3/es active Active
- 2011-03-25 PL PL11760333.2T patent/PL2552438T3/pl unknown
- 2011-03-25 JP JP2013501523A patent/JP5847156B2/ja active Active
- 2011-03-25 EP EP14200645.1A patent/EP2898884B1/en active Active
- 2011-03-25 HU HUE11760333A patent/HUE027749T2/en unknown
- 2011-03-25 AU AU2011230512A patent/AU2011230512B2/en active Active
- 2011-03-25 PT PT117603332T patent/PT2552438T/pt unknown
- 2011-03-25 CN CN201180025949.1A patent/CN103052385B/zh active Active
- 2011-03-25 CN CN201510242264.2A patent/CN104784121A/zh active Pending
- 2011-03-25 NZ NZ602382A patent/NZ602382A/en unknown
- 2011-03-25 MX MX2012010936A patent/MX346861B/es active IP Right Grant
- 2011-03-25 HR HRP20160609TT patent/HRP20160609T1/hr unknown
- 2011-03-25 WO PCT/US2011/030037 patent/WO2011119988A1/en not_active Ceased
- 2011-03-25 ES ES11760333.2T patent/ES2580135T3/es active Active
- 2011-03-28 TW TW100110703A patent/TWI495467B/zh active
-
2012
- 2012-09-11 IL IL221886A patent/IL221886A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/781,480 patent/US20140079787A1/en not_active Abandoned
-
2015
- 2015-04-28 JP JP2015091142A patent/JP2015134825A/ja active Pending
-
2016
- 2016-05-20 US US15/160,598 patent/US20160374952A1/en not_active Abandoned
- 2016-08-08 IL IL247171A patent/IL247171B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX359413B (es) | Metodos de tratamiento de carcinoma hepatocelular. | |
| CO6670567A2 (es) | Métodos de tratamiento contra el cáncer pancreático | |
| BR112012030699A2 (pt) | métodos para tratar câncer de bexiga | |
| MX364637B (es) | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. | |
| NI201200181A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
| PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
| MX393610B (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres | |
| BR112015016681A2 (pt) | métodos de tratamento de câncer pancreático | |
| IN2012DN02018A (enExample) | ||
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
| BR112016024020A8 (pt) | composição farmacêutica | |
| MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| CO7170176A2 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo | |
| CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| MX2014010749A (es) | Composicion ginecologica para tratar la vestibulitis vulvar. | |
| UA111158C2 (uk) | Спосіб комбінованої терапії для лікування проліферативних захворювань | |
| EA201892675A1 (ru) | Фармацевтическая композиция, содержащая этеплирсен | |
| CL2010001230A1 (es) | Metodo para inhibir la melanogenesis que comprende administrar un compuesto esteroidal; composicin farmaceutica; formulacion topica, util en el tratamiento de una enfermedad o condicion que involucra melanogenesis. | |
| MX2017011838A (es) | Composiciones y metodos para tratar carcinoma hepatocelular. | |
| UA112448C2 (uk) | Композиція і спосіб лікування аутоімунного захворювання | |
| HK1183814A (en) | Combination therapy methods for treating proliferative diseases | |
| HK1181666A (en) | Methods of treating cancer |